Antiplatelet therapy has shown promise in reducing the development of NASH and NASH-related HCC, mediated through platelet-specific glycoprotein Ib-α (GPIbα) and its interactions with platelets and inflammatory monocytes. Here, GP1BA is linked to metabolic dysfunction-associated steatohepatitis.